<DOC>
	<DOC>NCT00230763</DOC>
	<brief_summary>To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).</brief_summary>
	<brief_title>Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Male or female patients, Aged &gt; than equal to 18 years, Patient presenting with an OHT or OAG with an IOP ï¿½ 21 mmHg, Patient currently treated with ophthalmic betablockers monotherapy and requiring a change of the ophthalmic medication due to insufficient response to treatment, Patient currently treated by or having received within the last month any ophthalmic hypotensive agent other than a betablocker, Patient presenting any contraindication to latanoprost or timolol, Patient with history of asthma, obstructive bronchopneumopathy, sinusal bradycardia (pulse rate &lt; 60 bpm), auriculoventricular block, cardiac insufficiency, Raynaud disease or any other condition that would preclude the patient from taking the prescribed medication, Patient with known intolerance to benzalkonium chloride or any excipient contained in the trial treatment,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>